A novel small-molecule inhibitor of hepatitis C virus replication acts by suppressing signal transducer and activator of transcription 3

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 7, 2015, Pages 2013-2023

  Niu, Yuqiang ^a   Si, Youhui ^a   Li, Yan ^b   Chi, Xiaojing ^a   Li, Xiang ^a   Liu, Xiuying ^a   Li, Duan ^a   Cheng, Min ^a   Fan, Jingjing ^a   Si, Shuyi ^b   Yang, Wei ^a  

^a INSTITUTE OF PATHOGEN BIOLOGY   (China)

^b INSTITUTE OF MEDICINAL BIOTECHNOLOGY   (China)

Author keywords

Hepatitis C virus; IB 32; Inhibitor; N (cyclopropyl(phenyl)methyl)thieno 2,3 d pyrimidin 4 amine; STAT3

Indexed keywords

4 [[(4 METHYLPHENYL)SULFONYLOXY]ACETAMIDO]SALICYLIC ACID; ANTIVIRUS AGENT; INTERLEUKIN 6; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; N [CYCLOPROPYL(PHENYL)METHYL]THIENO[2,3 D]PYRIMIDIN 4 AMINE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN INHIBITOR; PROTEIN KINASE B; STA 21; STAT PROTEIN; STAT3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; WNT PROTEIN;

ARTICLE; ASSAY; CELL CULTURE; CELL LYSATE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISULFIDE BOND; DNA BINDING; DRUG CYTOTOXICITY; DRUG IDENTIFICATION; DRUG SCREENING; HEPATITIS C; HEPATOCELLULAR CARCINOMA CELL LINE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IC50; IMMUNOFLUORESCENCE; IN VITRO STUDY; LUCIFERASE ASSAY; LUNG CARCINOMA; MTT ASSAY; MULTIPLE CANCER; PROGENY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REPLICON; REPLICON CELL; REPORTER GENE ASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHABDOMYOSARCOMA CELL LINE; RNA REPLICATION; SIGNAL TRANSDUCTION; VIRUS ENTRY; VIRUS INFECTIVITY; VIRUS REPLICATION;

EID: 84936932847     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv077     Document Type: Article

References (34)

1. WHO. Hepatitis C. http://www.who.int/mediacentre/factsheets/fs164/en/.
2. Thomas DL. Global control of hepatitis C: where challenge meets opportunity. Nat Med 2013; 19: 850-8.
3. Dorner M, Horwitz JA, Donovan BM et al. Completion of the entire hepatitis C virus life cycle in genetically humanized mice. Nature 2013; 501: 237-41.
4. Pawlotsky JM. New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology 2014; 146: 1176-92.
5. Sheridan C. FDA approvals usher in the post-interferon era in HCV. Nat Biotechnol 2014; 32: 3-5.
6. Poveda E, Wyles DL, Mena A et al. Update on hepatitis C virus resistance to direct-acting antiviral agents. Antiviral Res 2014; 108: 181-91.
7. Halfon P, Sarrazin C. Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important? Liver Int 2012; 32 Suppl 1: 79-87.
8. Tai AW, Benita Y, Peng LF et al. A functional genomic screen identifies cellular cofactors of hepatitis C virus replication. Cell Host Microbe 2009; 5: 298-307.
9. Baugh JM, Garcia-Rivera JA, Gallay PA. Host-targeting agents in the treatment of hepatitis C: a beginning and an end? Antiviral Res 2013; 100: 555-61.
10. Zeisel MB, Lupberger J, Fofana I et al. Host-targeting agents for prevention and treatment of chronic hepatitis C-perspectives and challenges. J Hepatol 2013; 58: 375-84.
11. Goto K, LinW, Zhang L et al. The AMPK-related kinase SNARK regulates hepatitis C virus replication and pathogenesis through enhancement of TGF-beta signaling. J Hepatol 2013; 59: 942-8.
12. Andrus L, Marukian S, Jones CT et al. Expression of paramyxovirus V proteins promotes replication and spread of hepatitis C virus in cultures of primary human fetal liver cells. Hepatology 2011; 54: 1901-12.
13. Cheng M, Si Y, Yang Y et al. Recombinant human interleukin 28B: anti-HCV potency, receptor usage and restricted cell-type responsiveness. J Antimicrob Chemother 2012; 67: 1080-7.
14. Koutsoudakis G, Kaul A, Steinmann E et al. Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses. J Virol 2006; 80: 5308-20.
15. Yang W, Qiu C, Biswas N et al. Correlation of the tight junction-like distribution of Claudin-1 to the cellular tropism of hepatitis Cvirus. J Biol Chem 2008; 283: 8643-53.
16. Si Y, Liu S, Liu X et al. A human claudin-1-derived peptide inhibits hepatitis C virus entry. Hepatology 2012; 56: 507-15.
17. Qi Y, Xiang Y, Wang J et al. Inhibition of hepatitis C virus infection by polyoxometalates. Antiviral Res 2013; 100: 392-8.
18. McCartney EM, Helbig KJ, Narayana SK et al. Signal transducer and activator of transcription 3 is a proviral host factor for hepatitis C virus. Hepatology 2013; 58: 1558-68.
19. Gong G, Waris G, Tanveer R et al. Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-kappa B. Proc Natl Acad Sci USA 2001; 98: 9599-604.
20. Yoshida T, Hanada T, Tokuhisa T et al. Activation of STAT3 by the hepatitis C virus core protein leads to cellular transformation. J Exp Med 2002; 196: 641-53.
21. Ray S, Ju X, Sun H et al. The IL-6 trans-signaling-STAT3 pathway mediates ECM and cellular proliferation in fibroblasts from hypertrophic scar. J Invest Dermatol 2013; 133: 1212-20.
22. Waris G, Turkson J, Hassanein T et al. Hepatitis C virus (HCV) constitutively activates STAT-3 via oxidative stress: role of STAT-3 in HCV replication. J Virol 2005; 79: 1569-80.
23. Bromberg JF, Wrzeszczynska MH, Devgan G et al. Stat3 as an oncogene. Cell 1999; 98: 295-303.
24. Song H, Wang R, Wang S et al. A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc Natl Acad Sci USA 2005; 102: 4700-5.
25. Siddiquee K, Zhang S, Guida WC et al. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci USA 2007; 104: 7391-6.
26. Hassan NA, Shawali AS, Abu-Zied KM et al. Synthesis and antiviral evaluation of some new thieno [2, 3-d] pyrimidine S-glycosides. J Appl Sci Res 2013; 9: 833-42.
27. Aly AA, Brown AB, Ramadan M et al. Thieno[2, 3-d]pyrimidines in the synthesis of antitumor and antioxidant agents. Arch Pharm (Weinheim) 2010; 343: 301-9.
28. Darnell JE. Validating Stat3 in cancer therapy. Nat Med 2005; 11: 595-6.
29. Chiarle R, Simmons WJ, Cai H et al. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med 2005; 11: 623-9.
30. Zhang X, Yue P, Page BD et al. Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts. Proc Natl Acad Sci USA 2012; 109: 9623-8.
31. Yang F, VanMeter TE, Buettner R et al. Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas. Mol Cancer Ther 2008; 7: 3519-26.
32. Xiao F, Fofana I, Heydmann L et al. Hepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agents. PLoS Pathog 2014; 10: e1004128.
33. Adinolfi LE, Restivo L, Zampino R et al. Metabolic alterations and chronic hepatitis C: treatment strategies. Expert Opin Pharmacother 2011; 12: 2215-34.
34. Seden K, Back D, Khoo S. New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals. J Antimicrob Chemother 2010; 65: 1079-85.